Clinical Trial Details

Overview

Research Study Summary

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled trial of Ustekinumab, a Fully Human anti-IL-12/23p40 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis

Purpose

Do you have Psoriatic Arthritis? You may qualify to participate in a clinical research study.

Previously approved for the treatment of psoriasis, this agent is now being tested for BOTH biologic naïve as well as biologic exposed patients with psoriatic arthritis with active disease. This trial provides care for 108 weeks for biologic naïve patients and 60 weeks for patients with prior biologic exposure.

To Learn more

CW ID: 170025
Date Last Changed: July 23, 2013

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Duration
108 Weeks
Facility Type
N/A

Contact

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833

View Map

Research Center Information:

The Center for Rheumatology and Bone Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.